Baker McKenzie has acted for CLSA and other underwriters in connection with Joincare Pharmaceutical Group Industry, on global depositary receipts listing on the SIX Swiss Exchange. This transactions proves that the China-Switzerland Stock Connect has opened up new listing and fund-raising opportunities for Chinese issuers.
Joincare Pharmaceutical is an innovation-driven integrated pharmaceutical company that combines pharmaceutical R&D, manufacturing and commercialization. It is a pioneer and leader in the field of complex formulation in China. The company has been listed on the Shanghai Stock Exchange since June 2001.
The team, which provided the US and Swiss law advice, was led by partners Ivy Wong (Hong Kong), Thomas Tarala (Hong Kong) and Matthias Courvoisier (head of the capital markets practice, Zurich, pictured). They were assisted by a cross-office team of lawyers, including special counsel Bonnie Lau (Hong Kong) and associates Daisy Chen (Shanghai), Serena Shao (Beijing), Oliver He (Hong Kong), Yves Mauchle (Zurich) and Jan Lusti (Zurich). Besides acting as underwriters’ counsel in Joincare Pharmaceutical’s deal, Baker McKenzie had also served different roles in recent GDR listings involving companies in the energy, financial services and industrial manufacturing sectors, including as issuer’s counsel in GEM’s listing, underwriters’ counsel in Gotion High-tech’s listing, and depositary bank’s counsel in Keda Industrial Group and Ningbo Shanshan’s listings on SIX; and as issuer’s counsel in China Pacific Insurance’s listing and depositary bank’s counsel in Ming Yang Smart Energy Group’s listing on London Stock Exchange.